Tran Lucie, Pannier Bruno, Lacolley Patrick, Serrato Tomas, Benetos Athanase, London Gérard M, Bézie Yvonnick, Regnault Véronique
Department of Pharmacy, Groupe Hospitalier Paris Saint-Joseph, Paris, France; Department of Nephrology, Centre Hospitalier F.H. Manhès, Fleury-Mérogis, France; Université de Lorraine, Inserm, DCAC, Nancy, France.
Department of Nephrology, Centre Hospitalier F.H. Manhès, Fleury-Mérogis, France.
Kidney Int. 2021 May;99(5):1162-1172. doi: 10.1016/j.kint.2020.12.011. Epub 2020 Dec 22.
Endothelial dysfunction, one of many causes of arterial changes in end-stage kidney disease (kidney failure), is a likely link between early vascular aging and the risk of thrombosis or bleeding in this condition. To evaluate this, we compared links between arterial stiffness and endothelial/coagulation factors in 55 patients receiving hemodialysis therapy and 57 age-/sex-matched control individuals. Arterial stiffness was assessed from carotid-femoral pulse wave velocity, and coagulation status from the endogenous thrombin generating potential. Markers of endothelial dysfunction (von Willebrand factor, tissue factor pathway inhibitor), neutrophil extracellular traps and tissue factor-positive extracellular vesicles were higher in patients with kidney failure. Prothrombin fragments 1 and 2, and D-dimer markers of in vivo coagulation activation were also higher. However, in vitro in the presence of platelets, endogenous thrombin generating potential was lower and its downregulation by activated protein C impaired. Antiplatelet drugs did not affect these parameters. In multiple regression analysis, prothrombin fragments 1 and 2, D-dimer, factor VIII and monocyte-derived tissue factor-positive extracellular vesicles correlated with higher carotid-femoral pulse wave velocity. In patients with kidney failure, in vivo hypercoagulability occurred with reduced thrombin generation in platelet-rich plasma, likely explaining the opposing thrombotic and bleeding tendencies in patients with kidney failure. Importantly, arteriosclerosis is more closely related to a prothrombotic state. Thus, coagulation changes plus arterial stiffness highlight a major therapeutic challenge for anticoagulant and antiplatelet drug use.
内皮功能障碍是终末期肾病(肾衰竭)动脉变化的众多原因之一,它可能是早期血管老化与该病症中血栓形成或出血风险之间的联系。为了对此进行评估,我们比较了55例接受血液透析治疗的患者和57例年龄及性别匹配的对照个体的动脉僵硬度与内皮/凝血因子之间的联系。通过颈股脉搏波速度评估动脉僵硬度,通过内源性凝血酶生成潜力评估凝血状态。肾衰竭患者的内皮功能障碍标志物(血管性血友病因子、组织因子途径抑制剂)、中性粒细胞胞外诱捕网和组织因子阳性细胞外囊泡水平更高。凝血酶原片段1和2以及体内凝血激活的D - 二聚体标志物也更高。然而,在有血小板存在的体外实验中,内源性凝血酶生成潜力较低,且活化蛋白C对其下调作用受损。抗血小板药物不影响这些参数。在多元回归分析中,凝血酶原片段1和2、D - 二聚体、因子VIII以及单核细胞衍生的组织因子阳性细胞外囊泡与更高的颈股脉搏波速度相关。在肾衰竭患者中,富含血小板血浆中的凝血酶生成减少,但出现了体内高凝状态,这可能解释了肾衰竭患者血栓形成和出血倾向相反的现象。重要的是,动脉硬化与血栓前状态关系更为密切。因此,凝血变化加上动脉僵硬度凸显了抗凝和抗血小板药物使用的主要治疗挑战。